Roth Capital Initiates Solazyme With Buy

Roth Capital initiated coverage on shares of Solazyme SZYM with a Buy rating. The target price for Solazyme is set to $6. Solazyme shares have dropped 11.99% over the past 52 weeks, while the S&P 500 index has gained 15.82% in the same period. Solazyme's shares rose 2.04% to close at $7.49 yesterday.